Organigram Global Inc. OGI.TO

Company Overview

Organigram Global Inc. is a Canadian cannabis company focused on the cultivation, production, distribution, and commercialization of cannabis products for medical and adult-use recreational markets. The company operates primarily within the regulated cannabis industry and generates revenue through the sale of dried flower, pre-rolls, vapes, edibles, concentrates, and cannabis-derived products. Organigram is publicly traded on the Toronto Stock Exchange under the symbol OGI and on Nasdaq under OGI. Its principal customer base includes provincial cannabis distributors in Canada, medical cannabis patients, and, through strategic partnerships, emerging international cannabis markets.

The company traces its origins to Organigram Inc., founded in New Brunswick in 2010, and evolved from a medical cannabis producer into a broader consumer packaged goods-oriented cannabis business following Canadian legalization in 2018. Organigram has positioned itself as a scaled producer with a focus on operational efficiency, automated cultivation, product innovation, and brand development. Its strategic advantages include indoor cultivation expertise, a portfolio of established consumer brands, and access to capital and international partnerships that support product development and market expansion.

Business Operations

Organigram conducts operations through its primary cannabis production and commercialization activities in Canada. Its core operating assets include its flagship cultivation and manufacturing campus in Moncton, New Brunswick, along with additional processing and product development capabilities acquired through industry consolidation. Revenue is primarily generated through sales into Canadian provincial distribution systems and through branded consumer cannabis products marketed under labels including SHRED, Edison, Big Bag O’ Buds, and Trailblazer. The company has also expanded into international cannabinoid ingredient and export opportunities where permitted under local regulations.

The company maintains vertically integrated operations covering cultivation, extraction, formulation, manufacturing, packaging, and distribution. Organigram has invested heavily in automation, indoor growing technologies, and product innovation platforms designed to improve production consistency and margins. Strategic relationships have included investments and collaborations connected to cannabinoid science and international commercialization. Organigram has also benefited from equity investments and strategic cooperation arrangements associated with British American Tobacco, which has supported product research and development initiatives focused on next-generation cannabis products.

Strategic Position & Investments

Organigram’s strategic direction has centered on strengthening market share in Canada’s adult-use cannabis sector while pursuing higher-margin derivative products and international growth opportunities. The company has emphasized product innovation in categories such as edibles, inhalables, concentrates, and cannabinoid-based formulations. Management has also focused on operational efficiency, disciplined capital allocation, and scaling recognized consumer brands within the competitive Canadian cannabis market.

A major strategic development was the establishment of a product development collaboration with British American Tobacco plc, including the creation of a cannabinoid-focused research initiative known as Center of Excellence activities tied to advanced cannabis product development. Organigram has also pursued acquisitions and investments aimed at expanding manufacturing capacity, intellectual property, and brand portfolios. The company has participated in emerging sectors including cannabis biosynthesis research, next-generation delivery technologies, and international medical cannabis distribution channels where regulatory frameworks permit expansion.

Geographic Footprint

Organigram is headquartered in Toronto, Ontario, with major production operations located in Moncton, New Brunswick. Its primary commercial presence is in Canada, where it distributes products nationally through provincial wholesalers and retail systems across multiple provinces. The company has established broad penetration in the Canadian recreational cannabis market through its branded product portfolio and retail relationships.

Internationally, Organigram has explored and participated in export and partnership opportunities in regions including Europe, Australia, and select emerging medical cannabis jurisdictions. While its direct operational footprint outside Canada remains more limited than some multinational cannabis peers, the company has maintained international strategic ambitions through ingredient supply, cannabinoid research partnerships, and regulatory market development initiatives.

Leadership & Governance

Organigram operates under a corporate governance structure typical of publicly listed Canadian issuers, with oversight from its board of directors and executive leadership team. The company’s leadership strategy has emphasized disciplined growth, product innovation, operational efficiency, and long-term shareholder value creation within the evolving global cannabis sector. Public company disclosures and investor communications have consistently highlighted a focus on profitability improvement, brand leadership, and science-driven product development.

Key executives include:

• Beena Goldenberg – Chief Executive Officer
• Derrick West – Chief Financial Officer
• Paolo De Luca – Chief Strategy Officer
• Tim Emberg – Chief Commercial Officer
• Jared Simon – Chief Legal Officer and Corporate Secretary

Information regarding executive roles and organizational structure is based on recent public filings, investor materials, and company disclosures. Some leadership assignments may change over time based on corporate updates and public reporting cycles.